PMID- 25735953
OWN - NLM
STAT- MEDLINE
DCOM- 20160505
LR  - 20220317
IS  - 2326-6074 (Electronic)
IS  - 2326-6066 (Linking)
VI  - 3
IP  - 8
DP  - 2015 Aug
TI  - The Killer Cell Ig-like Receptor 2DL4 Expression in Human Mast Cells and Its 
      Potential Role in Breast Cancer Invasion.
PG  - 871-80
LID - 10.1158/2326-6066.CIR-14-0199 [doi]
AB  - The killer-cell Ig-like receptor (KIR) 2DL4 (CD158d) acts as a receptor for human 
      leukocyte antigen (HLA)-G and is expressed on almost all human natural killer 
      (NK) cells. The expression and function of KIR2DL4 in other hematopoietic cells 
      is poorly understood. Here, we focused on human mast cells, which exhibit 
      cytotoxic activity similar to that of NK cells. KIR2DL4 was detected in all 
      examined human cultured mast cells established from peripheral blood derived from 
      healthy volunteers (PB-mast), the human mast cell line LAD2, and human 
      nonneoplastic mast cells, including those on pathologic specimens. An agonistic 
      antibody against KIR2DL4 decreased KIT-mediated and IgE-triggered responses, and 
      enhanced the granzyme B production by PB-mast and LAD2 cells, by activating Src 
      homology 2-containing protein tyrosine phosphatase (SHP-2). Next, we performed a 
      coculture assay between LAD2 cells and the HLA-G(+) cancer cells, MCF-7 and 
      JEG-3, and showed that KIR2DL4 on LAD2 cells enhanced MMP-9 production and the 
      invasive activity of both cell lines via HLA-G. Immunohistochemical analysis 
      revealed that the direct interaction between HLA-G(+) breast cancer cells and 
      KIR2DL4(+) tissue mast cells (observed in 12 of 36 cases; 33.3%) was 
      statistically correlated with the presence of lymph node metastasis or 
      lymph-vascular invasion (observed in 11 of 12 cases; 91.7%; chi(2) = 7.439; P < 
      0.01; degrees of freedom, 1) in the clinical samples. These findings suggest that 
      the KIR2DL4 on human mast cells facilitates HLA-G-expressing cancer invasion and 
      the subsequent metastasis.
CI  - (c)2015 American Association for Cancer Research.
FAU - Ueshima, Chiyuki
AU  - Ueshima C
AD  - Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan. 
      Human Health Sciences, Kyoto University Graduate School of Medicine, Kyoto, 
      Japan.
FAU - Kataoka, Tatsuki R
AU  - Kataoka TR
AD  - Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan. 
      trkataoka@yahoo.co.jp.
FAU - Hirata, Masahiro
AU  - Hirata M
AD  - Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan.
FAU - Furuhata, Ayako
AU  - Furuhata A
AD  - Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan.
FAU - Suzuki, Eiji
AU  - Suzuki E
AD  - Department of Breast Surgery, Kyoto University Hospital, Kyoto, Japan.
FAU - Toi, Masakazu
AU  - Toi M
AD  - Department of Breast Surgery, Kyoto University Hospital, Kyoto, Japan.
FAU - Tsuruyama, Tatsuaki
AU  - Tsuruyama T
AD  - Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan.
FAU - Okayama, Yoshimichi
AU  - Okayama Y
AD  - Division of Molecular Cell Immunology and Allergology, Advanced Medical Research 
      Center, Nihon University Graduate School of Medical Science, Tokyo, Japan.
FAU - Haga, Hironori
AU  - Haga H
AD  - Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150303
PL  - United States
TA  - Cancer Immunol Res
JT  - Cancer immunology research
JID - 101614637
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (HLA-G Antigens)
RN  - 0 (Receptors, KIR2DL4)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - EC 2.7.10.1 (Proto-Oncogene Proteins c-kit)
RN  - EC 3.1.3.48 (PTPN11 protein, human)
RN  - EC 3.1.3.48 (Protein Tyrosine Phosphatase, Non-Receptor Type 11)
SB  - IM
MH  - Aged
MH  - Antibodies, Monoclonal/pharmacology
MH  - Biomarkers, Tumor
MH  - Breast Neoplasms/*genetics/*immunology/pathology/therapy
MH  - Cell Line, Tumor
MH  - Female
MH  - *Gene Expression
MH  - HLA-G Antigens/immunology/metabolism
MH  - Humans
MH  - Immunoglobulin E/immunology
MH  - Mast Cells/*immunology/*metabolism
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Neoplasm Invasiveness
MH  - Neoplasm Metastasis
MH  - Neoplasm Staging
MH  - Protein Binding
MH  - Protein Tyrosine Phosphatase, Non-Receptor Type 11/metabolism
MH  - Proto-Oncogene Proteins c-kit/metabolism
MH  - Receptors, KIR2DL4/antagonists & inhibitors/*genetics/metabolism
EDAT- 2015/03/05 06:00
MHDA- 2016/05/06 06:00
CRDT- 2015/03/05 06:00
PHST- 2014/10/22 00:00 [received]
PHST- 2015/02/24 00:00 [accepted]
PHST- 2015/03/05 06:00 [entrez]
PHST- 2015/03/05 06:00 [pubmed]
PHST- 2016/05/06 06:00 [medline]
AID - 2326-6066.CIR-14-0199 [pii]
AID - 10.1158/2326-6066.CIR-14-0199 [doi]
PST - ppublish
SO  - Cancer Immunol Res. 2015 Aug;3(8):871-80. doi: 10.1158/2326-6066.CIR-14-0199. 
      Epub 2015 Mar 3.